IRAK4 Inhibitor AZD2962

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with potential immunomodulating and antineoplastic activities. Upon oral administration, IRAK4 inhibitor AZD2962 targets, binds to, and inhibits the activity of IRAK4. This inhibits IRAK4-mediated signaling, prevents the activation of IRAK4-mediated nuclear factor-kappa B (NF-kB) signaling and decreases the expression of inflammatory cytokines and certain pro-survival factors. This inhibits proliferation of IRAK4-overactivated tumor cells, which are found in cells harboring MYD88 activating mutations or those with overactivated toll-like receptor (TLR) pathways. IRAK4, a serine/threonine-protein kinase that plays a key role in both the TLR and IL-1R signaling pathways, is activated though the adaptor protein MYD88 and links the TLR and IL-1R signaling pathway to the NF-kB pathway.

**Synonyms:** - AZD 2962 - AZD-2962 - AZD2962 - Interleukin-1 Receptor-associated Kinase 4 Inhibitor AZD2962